Pneumonia Therapeutics Market Expected To Secure Notable Revenue Share By 2026
Pneumonia Therapeutics Market Size is
expected to exceed USD 2.8 Bn by 2026. Increasing government initiatives for
the treatment of pneumonia will significantly accelerate the overall business
progression. Increasing incidence of pneumococcal disease worldwide will drive
the market growth from 2020 to 2026. Pneumococcal disease is caused by
Streptococcus pneumonia and can infect the lungs causing blood infection,
middle ear infection and bacterial meningitis among others.
The U.S. pneumonia
therapeutics market will witness around 6.3% CAGR and is projected to witness
substantial growth during the analysis period. The country growth
can be attributed due to increasing geriatric population base, leading to surging
demand for pneumonia therapeutic drugs. Additionally, increasing number of
hospital admissions for the treatment of pneumonia will enhance the country progression.
Based on drug class, the market is segmented into
antiviral drugs, antibacterial drugs and antifungal drugs. The antibacterial drugs
segment accounted for over 60% revenue share in 2019 and are further classified
into quinolones and macrolides among others. Antibacterial drugs are widely used to treat community-acquired
pneumonia. Furthermore, macrolides
antibiotics such as clarithromycin, azithromycin and others are useful for
children to protect them from pneumonia, thereby enhancing the segmental growth.
Based on the age group, the industry is segmented into
pediatric, adult and geriatric. The pediatric segment will exhibit 7.5% CAGR during
the analysis period. Children especially with weak immune system are at higher
risk of acquiring pneumonia. As child’s immune system is often weak and
underdeveloped, the chances of developing pneumonia are much higher. Also, children
having cystic fibrosis or asthma problems, and lungs associated disorders further
creates higher need for antiviral and antibacterial drugs. Thus, increased risk
of pneumonia in pediatric patients augments the segmental growth.
The infection type segment covers hospital acquired
pneumonia (HAP), community acquired pneumonia (CAP) and ventilator associated
pneumonia (VAP). The community acquired pneumonia segment accounted for around USD
1.3 Bn in 2019. CAP is one of the most common infectious diseases occurring worldwide.
CAP refers to the pneumonia that is acquired by individuals outside the
hospital. CAP is one of the most common cause of lung infections in people of 5
to 35 years of age. Increasing prevalence of community acquired pneumonia will
enhance the segmental growth.
Browse
key industry insights spread across 180 pages with 176 market data tables &
14 figures & charts from the report, “Pneumonia
Therapeutics Market Size By Drug Class (Antibacterial Drugs {Quinolones,
Macrolide}, Antiviral Drugs, Antifungal Drugs), By Age Group (Pediatric, Adult,
Geriatric), By Infection Type (Hospital-acquired Pneumonia (HAP),
Community-acquired Pneumonia (CAP), Ventilator-associated Pneumonia (VAP), By
Distribution Channel, (Hospital Pharmacies, Retail Pharmacies, Online
Pharmacies), Industry Analysis Report, Regional Outlook, Application Potential,
Price Trends, Competitive Market Share & Forecast, 2020 – 2026” in detail along with the table of contents: https://www.gminsights.com/industry-analysis/pneumonia-therapeutics-market
Some major findings of the pneumonia therapeutics market
report include:
- Increasing incidence of ventilator-associated and community-acquired bacterial pneumonia will boost the pneumonia therapeutics business growth
- Rising number of clinical trials for the development of new and more effective drug molecules will enhance the pneumonia therapeutics market growth
- Rising awareness among patients regarding pneumonia treatment aids the industry growth
- Surging incidence of pneumococcal disease among young population base across the globe will ultimately foster the market growth
Some of the prominent business players operating in
pneumonia therapeutics industry include Abbott Laboratories, Allergan, Bayer,
Cipla, Lupin Pharmaceuticals, Mylan, Novartis, Sanofi, Pfizer, Merck,
AstraZeneca and GlaxoSmithKline. These market players are focusing on
developing new products that helps the firm to expand its overall geographical
presence.
Request for customization: @ https://www.gminsights.com/roc/2029
About Global
Market Insights:
Global Market Insights, Inc., headquartered in Delaware,
U.S., is a global market research and consulting service provider; offering
syndicated and custom research reports along with growth consulting services.
Our business intelligence and industry research reports offer clients with
penetrative insights and actionable market data specially designed and
presented to aid strategic decision making. These exhaustive reports are
designed via a proprietary research methodology and are available for key
industries such as chemicals, advanced materials, technology, renewable energy
and biotechnology.
Contact Us:
Arun Hegde
Corporate Sales, USA
Global Market Insights, Inc.
Phone:1-302-846-7766
Toll Free: 1-888-689-0688
Comments
Post a Comment